Home

Prenetics Global Limited - Class A Ordinary Share (PRE)

7.0100
-1.0100 (-12.59%)
NASDAQ · Last Trade: Jun 14th, 5:23 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Competitors to Prenetics Global Limited - Class A Ordinary Share (PRE)

23andMe Holding Co. ME +0.00

23andMe competes directly with Prenetics by providing a consumer-friendly approach to DNA testing, offering ancestry and health-related insights. They adopt a subscription model that keeps customers engaged and encourages them to access new services and data over time. 23andMe's established brand recognition, large customer base, and strong marketing strategies provide a competitive advantage in the consumer genetics market.

Color Genomics, Inc.

Color Genomics focuses on providing affordable genetic testing, primarily targeting health and preventive measures. Their emphasis on next-generation sequencing and integrated digital health solutions makes them a formidable competitor to Prenetics. Color's partnerships with healthcare providers and employers help in distributing their testing services widely, giving them an advantage in reaching clinical audiences over Prenetics’ mainly consumer-driven approach.

Gene by Gene, Ltd.

Gene by Gene, offering ancestor and health genetic testing, competes with Prenetics primarily in the genealogical genetic testing space. They use a more traditional approach to DNA analysis, which attracts customers interested in ancestry rather than health. While they may not have the same level of technological integration as Prenetics, their specialization in genealogy can appeal to a distinct customer segment that values historical lineage over health insights.

Invitae Corporation

Invitae Corporation focuses on genetic information, offering a wide array of tests and services aimed at improving patient care. Similar to Prenetics, Invitae emphasizes the use of genetic testing for personal health insights, making them strong competitors in the direct-to-consumer genetic testing market. Invitae's extensive test menu, which covers various health conditions, and its partnerships with healthcare providers give it an edge in terms of credibility and trust in clinical settings.

Myriad Genetics, Inc. MYGN -3.08%

Myriad Genetics specializes in hereditary cancer testing and offers a range of other genetic tests targeting different health conditions. While Prenetics also offers genetic testing, Myriad’s established reputation within the oncology space, along with its focus on comprehensive genetic analysis for specific diseases, allows it to maintain a competitive edge in targeted markets. The extensive clinical data and partnerships Myriad has developed bolster its competitive position.